13.26  -0.04 (-0.3%)		03-05 16:00
Open: 13.11 High: 13.285 Volume: 1,497,391		Pre. Close: 13.3 Low: 13 Market Cap: 4,168(M)

Short term
Mid term
Targets	6-month :	16.93	1-year :	18.01
Resists	First :	14.49	Second :	15.42
Pivot price	14.27
Supports	First :	13	Second :	10.81
MAs	MA(5) :	13.49	MA(20) :	14.37
	MA(100) :	12.56	MA(250) :	10.07
MACD	MACD :	-0.1	Signal :	0.1
%K %D	K(14,3) :	9.9	D(3) :	13.2
RSI	RSI(14): 35.1
52-week	High :	15.42	Low :	6.68

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ AMRX ] has closed above bottom band by 7.7%. Bollinger Bands are 79% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.

If tomorrow:	Open lower	Open higher
High:	13.37 - 13.5	13.5 - 13.58
Low:	12.73 - 12.89	12.89 - 13
Close:	13.06 - 13.34	13.34 - 13.51

Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories. The Specialty segment is involved in the development, promotion, distribution, and sale of branded pharmaceutical products with focus on central nervous system disorders, endocrinology, parasitic infections, and other therapeutic areas. It also offers Emverm, a chewable tablet for the treatment of pinworm, whipworm, common roundworm, common hookworm, and American hookworm in single or mixed infections; Rytary to treat Parkinson's disease; and Unithroid for the treatment of hypothyroidism. The AvKARE segment provides pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. It is also involved in the wholesale distribution of bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names, as well as medical and surgical products; and packaging and wholesale distribution of pharmaceuticals and vitamins to its retail and institutional customers. The company sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. It operates in the United States, India, Ireland, and internationally. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.

Thu, 05 Mar 2026
Amneal to Participate in Upcoming Investor Conference - The Manila Times

Thu, 05 Mar 2026
Amneal co-chief to speak at Miami Barclays healthcare investor event - Stock Titan

Tue, 03 Mar 2026
AMRX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan

Tue, 03 Mar 2026
Amneal Pharmaceuticals, Inc. $AMRX Shares Purchased by Vanguard Group Inc. - MarketBeat

Tue, 03 Mar 2026
Short Interest in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Drops By 16.4% - MarketBeat

Mon, 02 Mar 2026
Amneal Q4 2025 Highlights Shift Toward Higher Value Pharma Segments - Sahm

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Neutral
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Shares Out	314 (M)
Shares Float	191 (M)
Held by Insiders	46.5 (%)
Held by Institutions	50 (%)
Shares Short	12,690 (K)
Shares Short P.Month	6,850 (K)

EPS	0
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	-0.35
Profit Margin	0.2 %
Operating Margin	11.8 %
Return on Assets (ttm)	6.7 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	11.6 %
Gross Profit (p.s.)	3.46
Sales Per Share	9.32
EBITDA (p.s.)	1.98
Qtrly Earnings Growth	0 %
Operating Cash Flow	328 (M)
Levered Free Cash Flow	219 (M)

PE Ratio	1326
PEG Ratio	0
Price to Book value	-37.89
Price to Sales	1.42
Price to Cash Flow	12.71

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.